Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning
Author:
Funder
Office of Naval Research
National Institutes of Health
Health Resources and Services Administration
Publisher
Elsevier BV
Subject
Transplantation,Hematology
Reference40 articles.
1. Optimal prevention of seizures induced by high-dose busulfan;Eberly;Pharmacotherapy,2008
2. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation;Mielcarek;Blood,2016
3. Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients;Floeter;J Oncol Pharm Pract,2017
4. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes;Rezvani;Biol Blood Marrow Transplant,2013
5. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy;McCune;Clin Pharmacol Ther,2009
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center;Cancer Medicine;2024-05
2. The presence of busulfan metabolites and pharmacometabolomics in plasma drawn immediately before allograft infusion in hematopoietic cell transplant recipients;Clinical and Translational Science;2023-10-10
3. Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients;Journal of Oncology Pharmacy Practice;2023-05-03
4. Optimal regimen of levetiracetam for prevention of busulfan-induced seizure in patients undergoing hematopoietic stem cell transplantation: A review of available evidence;Journal of Oncology Pharmacy Practice;2023-02-27
5. Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions;Expert Opinion on Drug Metabolism & Toxicology;2023-02-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3